Premium
Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population‐based Study
Author(s) -
Yang SY,
Kao Yang YH,
Chong MY,
Yang YH,
Chang WH,
Lai CS
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100069
Subject(s) - quetiapine , risperidone , olanzapine , thioridazine , clozapine , antipsychotic , medicine , extrapyramidal symptoms , population , haloperidol , chlorpromazine , psychiatry , schizophrenia (object oriented programming) , environmental health , dopamine
To compare the prevalence of extrapyramidal syndrome (EPS) between the first‐generation antipsychotics (FGAs) and second‐generation antipsychotics (SGAs), the co‐prescribing rate of anti‐Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5‐year study period. Among the SGAs, quetiapine had the lowest crude co‐prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the FGAs, thioridazine and loxapine had the lowest (60.99%) and highest rates (96.35%), respectively. The rankings of the co‐prescribing rate of APDs among antipsychotics, in increasing order, were quetiapine, clozapine, olanzapine, thioridazine, zotepine, chlorpromazine, risperidone, sulpiride, clotiapine, flupentixol, haloperidol, zuclopentixol, trifluoperazine, and loxapine. The results indicate that the risk of EPS appears to be lower in SGAs than in FGAs; however, the considerably high rate of EPS in some of the newer generation of antipsychotics warrants clinical attention. Clinical Pharmacology & Therapeutics (2007) 81 , 586–594. doi: 10.1038/sj.clpt.6100069 ; published online 18 January 2007